First-in-human, phase I dose-escalation study of investigational drug MLN9708, a second-generation proteasome inhibitor, in advanced nonhematologic malignancies.

被引：2
|
作者：
Rodler, E. T.
Infante, J. R.
Siu, L. L.
Smith, D. C.
Sullivan, D.
Vlahovic, G.
Gomez-Navarro, J.
Liu, G.
Blakemore, S.
Thompson, A.
机构：
[1] Seattle Canc Care Alliance, Seattle, WA USA
[2] Sarah Cannon Res Inst & Tennessee Oncol, Nashville, TN USA
[3] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[4] Univ Michigan, Ctr Canc, Ann Arbor, MI 48109 USA
[5] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[6] Duke Univ, Med Ctr, Durham, NC USA
[7] Millennium Pharmaceut Inc, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.3071
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3071
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase 1 Study of MLN9708, an Investigational Proteasome Inhibitor, in Advanced Nonhematologic Malignancies- Updated Results
    Smith, D. C.
    Infante, J. R.
    Siu, L. L.
    Sullivan, D.
    Vlahovic, G.
    Kauh, J.
    Blakemore, S. J.
    Gupta, N.
    Kalebic, T.
    Thompson, J. A.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S147 - S147
  • [2] MLN9708, a Novel, Investigational Proteasome Inhibitor, in Patients with Relapsed/Refractory Lymphoma: Results of a Phase 1 Dose-Escalation Study
    Assouline, Sarit
    Chang, Julie
    Rifkin, Robert
    Hui, Ai-Min
    Berg, Deborah
    Gupta, Neeraj
    Xi, Yingmei
    Di Bacco, Alessandra
    Martin, Peter
    [J]. BLOOD, 2011, 118 (21) : 1148 - 1148
  • [3] MLN9708, an investigational proteasome inhibitor, in patients (pts) with relapsed/refractory lymphoma: Emerging data from a phase I dose-escalation study.
    Martin, Peter
    Chang, Julie E.
    Rifkin, Robert M.
    Hui, Ai-Min
    Berg, Deborah
    Gupta, Neeraj
    Liu, Guohui
    Di Bacco, Alessandra
    Assouline, Sarit E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] ONCE-WEEKLY MLN9708, AN INVESTIGATIONAL PROTEASOME INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY LYMPHOMA: RESULTS OF A PHASE 1 DOSE-ESCALATION STUDY
    Assouline, S.
    Chang, J.
    Rifkin, R.
    Hui, A-M
    Gupta, N.
    Yu, J.
    Di Bacco, A.
    Shou, Y.
    Martin, P.
    [J]. HAEMATOLOGICA, 2012, 97 : 434 - 434
  • [5] Results of a Phase 1 Dose-Escalation Study of Once-Weekly MLN9708, an Investigational Proteasome Inhibitor, in Patients with Relapsed/Refractory Lymphoma
    Assouline, Sarit
    Chang, Julie E.
    Cheson, Bruce D.
    Rifkin, Robert
    Hamburg, Solomon
    Reyes, Ruben
    Hui, Ai-Min
    Yu, Jiang
    Gupta, Neeraj
    Di Bacco, Alessandra
    Shou, Yaping
    Martin, Peter
    [J]. BLOOD, 2012, 120 (21)
  • [6] First-in-human, multicenter, dose-escalation, phase I study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced nonhematologic malignancies and melanoma.
    Sosman, J. A.
    Adjei, A. A.
    LoRusso, P.
    Michael, S. A.
    Dy, G. K.
    Bowditch, A.
    Chmielowski, B.
    Lee, S.
    Walker, R. M.
    Faucette, S.
    Izmailova, E. S.
    Bozon, V.
    Ribas, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [7] Weekly Dosing of the Investigational Oral Proteasome Inhibitor MLN9708 in Patients with Relapsed and/or Refractory Multiple Myeloma: Results From a Phase 1 Dose-Escalation Study
    Kumar, Shaji
    Bensinger, William I.
    Reeder, Craig B.
    Zimmerman, Todd M.
    Berenson, James R.
    Berg, Deborah
    Liu, Guohui
    Gupta, Neeraj
    Di Bacco, Alessandra
    Hui, Ai-Min
    Niesvizky, Ruben
    [J]. BLOOD, 2011, 118 (21) : 371 - 372
  • [8] Phase I dose-escalation study of the investigational Aurora A kinase (AAK) inhibitor MLN8237 as an enteric-coated tablet (ECT) formulation in patients with nonhematologic malignancies.
    Sharma, S.
    Kurzrock, R.
    Gouw, L.
    Hong, D. S.
    Jones, K.
    Zhou, X.
    Shi, H.
    Fingert, H.
    Falchook, G. S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [9] ANTITUMOR ACTIVITY OF THE INVESTIGATIONAL DRUG MLN9708, A SECOND-GENERATION PROTEASOME INHIBITOR, IN PRECLINICAL MODELS OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
    Berger, A.
    Donelan, J.
    Lee, E.
    Bannerman, B.
    Bano, K.
    Babcock, T.
    Cao, Y.
    Fitzgerald, M.
    Hales, P.
    Koenig, E.
    Lightcap, E.
    Mazzola, A.
    Smith, P.
    Stringer, B.
    Yang, Y.
    Yu, J.
    Zhang, J.
    Fleming, P.
    Kupperman, E.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 467 - 467
  • [10] First-in-human, phase I, dose-escalation study of selective PI3Kα isoform inhibitor MLN1117 in patients (pts) with advanced solid malignancies.
    Juric, Dejan
    De Bono, Johann Sebastian
    LoRusso, Patricia
    Nemunaitis, John J.
    Heath, Elisabeth I.
    Kwak, Eunice Lee
    Macarulla, Teresa
    Geuna, Elena
    Luken, Maria Jose de Miguel
    Patel, Chirag
    Kuida, Keisuke
    Sankoh, Serap
    Zohren, Fabian
    Shou, Yaping
    Tabernero, Josep
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345